NAD+: Strong Trials on Blood Levels, Thin Data on Outcomes

Start here

NAD+ is a molecule every cell needs to make energy. It shuttles electrons through the reactions that turn food into ATP, and it also feeds a separate set of enzymes — sirtuins, PARPs — that repair DNA and regulate genes. Levels of it fall with age.

Swallowing NAD+ directly doesn't work well; it's broken down before it can enter cells intact. That's why the actual research, and the actual market, centers on precursors: NMN and NR, smaller molecules the body converts into NAD+. Multiple placebo-controlled human trials have tested these precursors and consistently found they raise blood NAD+ ^[7][10]. What's less settled is whether that translates into a measurable clinical outcome ^[6].

Nothing here is a supplement recommendation. It's a summary of what specific trials, at specific doses, actually found.

What it is

NAD+ — nicotinamide adenine dinucleotide — is built from two smaller units joined by a phosphate bridge: a nicotinamide half and an adenine half. It exists in two interconvertible forms, oxidized (NAD+) and reduced (NADH), and that redox pair is the currency cells use to move electrons through metabolism.

Beyond energy production, NAD+ is consumed — not just recycled — by a set of signaling enzymes: sirtuins, which regulate gene expression and cell survival; PARP1, which repairs damaged DNA; and CD38, an enzyme that increases with age and inflammation and eats into the available NAD+ pool ^[9]. That competition for a shrinking pool is the mechanistic basis for the whole NAD+-boosting field.

How it works

Raising NAD+ works by supplying more of the precursor the salvage pathway needs. NMN sits one enzymatic step from NAD+; NR sits two steps away. Both are converted through NAMPT, the rate-limiting enzyme in that pathway, which also declines with age.

Once elevated, NAD+ feeds sirtuins and PARP1 more substrate, the proposed route to better DNA repair and mitochondrial function. In a randomized trial, ten weeks of oral NMN improved muscle insulin sensitivity in prediabetic, postmenopausal women, measured directly with a hyperinsulinemic-euglycemic clamp — a rigorous, gold-standard test ^[8]. Body composition and HbA1c did not change in that same trial. Raising the coenzyme moved one metabolic marker without moving others.

What the research shows

A 2023 multicenter, double-blind RCT gave adults 300 to 900 mg of oral NMN daily for 60 days. Blood NAD+ rose in a dose-dependent way at both 30 and 60 days across every dose tested, and walking distance and quality-of-life scores improved versus placebo; 600 mg/day was identified as the optimal dose tested, with no safety concerns at any level ^[7].

A separate 8-week RCT tested NR at 100, 300, and 1000 mg/day in healthy overweight adults. Whole-blood NAD+ rose 22%, 51%, and 142% respectively, a clean dose-response curve, with no flushing and no meaningful difference in adverse events from placebo ^[10].

In prediabetic, postmenopausal women, ten weeks of NMN improved muscle insulin sensitivity on formal clamp testing, without changing body composition or HbA1c ^[8].

Zooming out, a 2025 review of the human clinical evidence concluded that trials have shown limited efficacy so far, that the age-related NAD+ decline itself has only been directly observed in a limited number of human studies, and that tissue-specific NAD+ data remain sparse — the field needs more clinical study, not more rodent extrapolation ^[6]. A separate foundational review lays out why the mechanism is plausible even where outcome trials lag: NAD+ is consumed by the same enzymes implicated in aging biology ^[9].

Reported effects, cautions & safety

NAD+ doesn't have the same volume of community self-report as the other three compounds on this desk, so this section leans on documented, literature-level cautions rather than anecdote.

The clearest safety issue concerns delivery method, not the molecule itself. Compounded, injectable NAD+ is marketed aggressively as an IV wellness therapy, but the FDA issued a Class I recall — its most serious category — against a compounded NAD+ injection over elevated bacterial endotoxin. Infused NAD+ also clears from plasma quickly, and running an infusion too fast is linked to chest or abdominal discomfort, flushing, and nausea.

On the supplement side, oral NAD+ itself is poorly absorbed intact — the reason precursor trials test NMN and NR instead of NAD+ directly. NMN's regulatory status is unsettled too: the FDA has taken the position that NMN is excluded from the dietary-supplement definition because it was investigated as a drug first, creating marketplace uncertainty independent of the biology.

One mechanistic caution is worth stating plainly: NAD+ supports the metabolism of any proliferating cell, including an existing cancer. That's a theoretical concern raised in the literature, not a demonstrated clinical outcome — but it's the reason some clinicians advise caution in active-cancer populations. None of the trial data above tested cancer patients.

Where it fits in Research Peptide Fundamentals

NAD+ occupies a different category than the other three compounds here — it isn't a drug candidate, it's a coenzyme the body already makes, sold as a supplement and, compounded, as an injectable. Its trial base is real: multiple RCTs on precursor dosing, done well, published recently ^[7][10]. What it doesn't have yet is a hard clinical-outcome trial — a study that raised NAD+ and then measured a disease-relevant endpoint, the way tirzepatide's trials measured weight loss directly ^[16].

That gap is explicit in the most current review of the field, which called for more clinical study rather than continued reliance on animal data ^[6]. See the comparison page for how NAD+'s trial depth stacks up against the other three.